Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

BACKGROUND: Patients with classical Hodgkin lymphoma (cHL) relapsed or refractory (R/R) disease who relapse after or are ineligible for autologous stem cell transplantation have a poor prognosis. Recently, the anti-PD1 monoclonal antibodies nivolumab and pembrolizumab were approved by the US Food an...

Descripción completa

Detalles Bibliográficos
Autores principales: Laliberté, François, Raut, Monika, Yang, Xiaoqin, Germain, Guillaume, Nahar, Akash, Desai, Kaushal D., MacKnight, Sean D., Sen, Shuvayu S., Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810643/
https://www.ncbi.nlm.nih.gov/pubmed/33284424
http://dx.doi.org/10.1007/s11523-020-00778-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810643/
https://www.ncbi.nlm.nih.gov/pubmed/33284424
http://dx.doi.org/10.1007/s11523-020-00778-y

Ejemplares similares